Key Takeaways
- Approximately 2.8% of U.S. adults experience binge eating disorder (BED) at some point in their lifetime, with higher rates among women (3.5%) than men (2.0%)
- The 12-month prevalence of BED in U.S. adults is 1.25%, affecting about 3 million individuals annually
- Among U.S. adolescents aged 13-18, the lifetime prevalence of BED is 2.3%, with 1.6% in the past year
- Genetic factors account for 40-50% of the heritability of binge eating episodes in BED
- Childhood obesity increases BED risk by 2.7-fold (OR=2.72, 95% CI 1.75-4.23)
- History of dieting before age 18 raises BED lifetime risk by 3 times
- BED diagnostic criteria require recurrent binge eating episodes at least once a week for 3 months
- Binge episodes involve eating an abnormally large amount of food with loss of control, lasting ~2 hours on average
- Marked distress about binge eating occurs in 98% of BED patients
- Cognitive-behavioral therapy (CBT) achieves 50-60% abstinence from binges at post-treatment
- Lisdexamfetamine (Vyvanse) reduces binge days/week by 3.87 (vs 2.51 placebo) in 11-week trial
- Interpersonal psychotherapy (IPT) yields 40% remission rate at 1-year follow-up for BED
- 60% of BED patients have lifetime major depressive disorder (MDD)
- Obesity class II-III present in 70% of BED cases at diagnosis
- Lifetime anxiety disorders (GAD, panic) in 60-80% of BED patients
Binge Eating Disorder affects millions of people and is treatable with therapy and medication.






